Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of <i>Mycobacterium tuberculosis</i> Growth
Peter C. Ray, Margaret Huggett, Penelope A. Turner, Malcolm Taylor, Laura A. T. Cleghorn, Julie V. Early, Anuradha Kumar, Shilah A. Bonnett, Lindsay Flint, Douglas Joerss, James Johnson, Aaron Korkegian, Steven F. Mullen, Abraham L. Moure, Susan H. Davis, Dinakaran Murugesan, Michael Mathieson, Nicola Caldwell, Curtis A. Engelhart, Dirk Schnappinger, Ola Epemolu, Fabio Zuccotto, Jennifer Riley, Paul Scullion, Laste Stojanovski, Lisa M. Massoudi, Gregory T. Robertson, Anne J. Lenaerts, Gail Freiberg, Dale J. Kempf, Thierry Masquelin, Philip A. Hipskind, Joshua Odingo, Kevin D. Read, Simon R. Green, Paul G. Wyatt, Tanya Parish
Abstract
exposure remaining above the minimal inhibitory concentration for only a limited time.
Topics & Concepts
hERGMycobacterium tuberculosisChemistryCytotoxicityBiochemistryIn vitroPotassium channelPharmacologyTuberculosisBiologyMedicineBiophysicsPathologyTuberculosis Research and EpidemiologyCancer therapeutics and mechanismsPhenothiazines and Benzothiazines Synthesis and Activities